BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 38828195)

  • 1. Brain Targeting Nanomedicines: Pitfalls and Promise.
    Kakinen A; Jiang Y; Davis TP; Teesalu T; Saarma M
    Int J Nanomedicine; 2024; 19():4857-4875. PubMed ID: 38828195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in nanomedicine for the treatment of Alzheimer's and Parkinson's diseases.
    Hernando S; Gartziandia O; Herran E; Pedraz JL; Igartua M; Hernandez RM
    Nanomedicine (Lond); 2016 May; 11(10):1267-85. PubMed ID: 27077453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoparticle-Based Technology Approaches to the Management of Neurological Disorders.
    Sim TM; Tarini D; Dheen ST; Bay BH; Srinivasan DK
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32842530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanoparticles for Targeted Brain Drug Delivery: What Do We Know?
    Pinheiro RGR; Coutinho AJ; Pinheiro M; Neves AR
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Brain Tumors with Nanomedicines: Overcoming Blood Brain Barrier Challenges.
    Khaitan D; Reddy PL; Ningaraj N
    Curr Clin Pharmacol; 2018; 13(2):110-119. PubMed ID: 29651960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Therapeutic Benefits of Intravenously Administrated Nanoparticles in Stroke and Age-related Neurodegenerative Diseases.
    Farhoudi M; Sadigh-Eteghad S; Mahmoudi J; Farjami A; Mahmoudian M; Salatin S
    Curr Pharm Des; 2022; 28(24):1985-2000. PubMed ID: 35676838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanotechnology-based Drug Delivery for Alzheimer's and Parkinson's Diseases.
    Nguyen-Thi PT; Ho TT; Nguyen TT; Vo GV
    Curr Drug Deliv; 2024; 21(7):917-931. PubMed ID: 37424345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multifunctional Nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging.
    Bhaskar S; Tian F; Stoeger T; Kreyling W; de la Fuente JM; Grazú V; Borm P; Estrada G; Ntziachristos V; Razansky D
    Part Fibre Toxicol; 2010 Mar; 7():3. PubMed ID: 20199661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Active Targeting Towards and Inside the Brain based on Nanoparticles: A Review.
    Rabiei M; Kashanian S; Samavati SS; Jamasb S; McInnes SJP
    Curr Pharm Biotechnol; 2020; 21(5):374-383. PubMed ID: 31793421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanomedicine against Alzheimer's and Parkinson's Disease.
    Tandon A; Singh SJ; Chaturvedi RK
    Curr Pharm Des; 2021; 27(12):1507-1545. PubMed ID: 33087025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanomedicines for the Treatment of CNS Diseases.
    Reynolds JL; Mahato RI
    J Neuroimmune Pharmacol; 2017 Mar; 12(1):1-5. PubMed ID: 28150132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treating Alzheimer's disease using nanoparticle-mediated drug delivery strategies/systems.
    Roghani AK; Garcia RI; Roghani A; Reddy A; Khemka S; Reddy RP; Pattoor V; Jacob M; Reddy PH; Sehar U
    Ageing Res Rev; 2024 Jun; 97():102291. PubMed ID: 38614367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of nanomedicines for the treatment of Alzheimer's disease: Raison d'être, strategies, challenges and regulatory aspects.
    Mazahir F; Alam MI; Yadav AK
    Ageing Res Rev; 2024 Jul; 98():102318. PubMed ID: 38705362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell-Penetrating Peptides: Promising Therapeutics and Drug-Delivery Systems for Neurodegenerative Diseases.
    Pirhaghi M; Mamashli F; Moosavi-Movahedi F; Arghavani P; Amiri A; Davaeil B; Mohammad-Zaheri M; Mousavi-Jarrahi Z; Sharma D; Langel Ü; Otzen DE; Saboury AA
    Mol Pharm; 2024 May; 21(5):2097-2117. PubMed ID: 38440998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanotechnology-mediated nose to brain drug delivery for Parkinson's disease: a mini review.
    Kulkarni AD; Vanjari YH; Sancheti KH; Belgamwar VS; Surana SJ; Pardeshi CV
    J Drug Target; 2015; 23(9):775-88. PubMed ID: 25758751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanotechnology-based drug delivery systems for the treatment of Alzheimer's disease.
    Fonseca-Santos B; Gremião MP; Chorilli M
    Int J Nanomedicine; 2015; 10():4981-5003. PubMed ID: 26345528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic Strategies for Alzheimer's and Parkinson's Diseases by Means of Drug Delivery Systems.
    Cunha S; Amaral MH; Lobo JM; Silva AC
    Curr Med Chem; 2016; 23(31):3618-3631. PubMed ID: 27554805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of Current Strategies for Delivering Alzheimer's Disease Drugs across the Blood-Brain Barrier.
    Wong KH; Riaz MK; Xie Y; Zhang X; Liu Q; Chen H; Bian Z; Chen X; Lu A; Yang Z
    Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30658419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Micro- and nanotechnology approaches to improve Parkinson's disease therapy.
    Torres-Ortega PV; Saludas L; Hanafy AS; Garbayo E; Blanco-Prieto MJ
    J Control Release; 2019 Feb; 295():201-213. PubMed ID: 30579984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exosome-Based Macromolecular neurotherapeutic drug delivery approaches in overcoming the Blood-Brain barrier for treating brain disorders.
    Yadav K; Vijayalakshmi R; Kumar Sahu K; Sure P; Chahal K; Yadav R; Sucheta ; Dubey A; Jha M; Pradhan M
    Eur J Pharm Biopharm; 2024 Jun; 199():114298. PubMed ID: 38642716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.